Jula Inrig Sells 2,066 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider Jula Inrig sold 2,066 shares of the company’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $19.10, for a total transaction of $39,460.60. Following the transaction, the insider now directly owns 59,883 shares of the company’s stock, valued at approximately $1,143,765.30. This trade represents a 3.34 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Jula Inrig also recently made the following trade(s):

• On Monday, January 6th, Jula Inrig sold 440 shares of Travere Therapeutics stock. The shares were sold at an average price of $18.76, for a total value of $8,254.40.

Travere Therapeutics Stock Down 0.8 %

Shares of TVTX traded down $0.15 on Monday, hitting $18.71. 1,356,877 shares of the stock traded hands, compared to its average volume of 1,230,192. Travere Therapeutics, Inc. has a one year low of $5.12 and a one year high of $20.33. The company has a market capitalization of $1.46 billion, a PE ratio of -4.11 and a beta of 0.70. The business has a 50 day simple moving average of $18.14 and a 200 day simple moving average of $13.90. The company has a debt-to-equity ratio of 24.96, a quick ratio of 1.68 and a current ratio of 1.71.

Travere Therapeutics (NASDAQ:TVTX) last posted its earnings results on Thursday, October 31st. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.01. The business had revenue of $62.90 million during the quarter, compared to the consensus estimate of $60.87 million. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%. The firm’s revenue was up 69.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.17) EPS. As a group, equities analysts forecast that Travere Therapeutics, Inc. will post -3.94 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Travere Therapeutics

Large investors have recently made changes to their positions in the company. Millennium Management LLC boosted its holdings in shares of Travere Therapeutics by 33.9% in the second quarter. Millennium Management LLC now owns 2,949,335 shares of the company’s stock worth $24,244,000 after buying an additional 747,406 shares during the last quarter. Emerald Advisers LLC raised its position in Travere Therapeutics by 19.8% in the third quarter. Emerald Advisers LLC now owns 1,960,659 shares of the company’s stock worth $27,430,000 after acquiring an additional 323,513 shares during the period. Finepoint Capital LP boosted its stake in shares of Travere Therapeutics by 0.3% during the 3rd quarter. Finepoint Capital LP now owns 1,782,267 shares of the company’s stock worth $24,934,000 after acquiring an additional 5,539 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Travere Therapeutics by 3.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,731,045 shares of the company’s stock valued at $24,222,000 after acquiring an additional 64,744 shares during the period. Finally, Emerald Mutual Fund Advisers Trust increased its stake in shares of Travere Therapeutics by 26.0% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 1,185,709 shares of the company’s stock worth $16,588,000 after purchasing an additional 244,444 shares in the last quarter.

Analyst Ratings Changes

Several equities analysts have recently issued reports on TVTX shares. Citigroup reduced their target price on Travere Therapeutics from $23.00 to $19.00 and set a “buy” rating on the stock in a research note on Friday, September 27th. Wells Fargo & Company raised shares of Travere Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $9.00 to $27.00 in a research report on Monday, October 21st. Leerink Partners restated an “outperform” rating and issued a $20.00 price objective on shares of Travere Therapeutics in a report on Tuesday, October 8th. Piper Sandler lifted their target price on shares of Travere Therapeutics from $12.00 to $22.00 and gave the company a “neutral” rating in a research note on Thursday, November 14th. Finally, Canaccord Genuity Group decreased their price target on shares of Travere Therapeutics from $23.00 to $22.00 and set a “buy” rating for the company in a research note on Monday, September 30th. One equities research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $23.67.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.